Risk of healthcare cost-containment measures and drug price reductions
First written in FY2020. 4 of 5 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2018: 21 of 67 companies on the "Worse" side.
48 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「In addition, the regenerative medicine and pharmaceutical industries continue to face many challenges, including adjustments to pricing and reimbursement systems that are aligned with healthcare finances.」
Adjustments to pricing and reimbursement systems, including alignment with healthcare finances, have been reconfirmed as an ongoing challenge for the regenerative medicine and pharmaceutical industries. - FY2025RestatedAnnual report
「Governments around the world have indicated policies to curb the growth of healthcare spending in order to rein in continually rising costs, and measures such as regular reductions in drug prices and the promotion of generic drug use are progressing.」
The risk that healthcare cost-containment measures, lower drug prices and the promotion of generic drugs may affect operating results and financial position has been reconfirmed. - FY2024RestatedAnnual report
「Governments around the world have indicated policies to curb the growth of healthcare spending in order to rein in continually rising costs, and measures such as regular reductions in drug prices and the promotion of generic drug use are progressing.」
The risk that healthcare cost-containment measures, lower drug prices and the promotion of generic drugs may affect operating results and financial position has been reconfirmed. - FY2022RestatedAnnual report
「Governments around the world have indicated policies to curb the growth of healthcare spending in order to rein in continually rising costs, and measures such as regular reductions in drug prices and the promotion of generic drug use are progressing.」
The risk that healthcare cost-containment measures, lower drug prices and the promotion of generic drugs may affect operating results and financial position has been reconfirmed. - FY2020First statedAnnual report
「Governments around the world have indicated policies to curb the growth of healthcare spending in order to rein in continually rising costs, and measures such as regular reductions in drug prices and the promotion of generic drug use are progressing. Future developments in healthcare spending policies may have a significant impact on the Company's operating results and financial position.」
The potential impact of healthcare cost containment, lower drug prices and the promotion of generic drugs in various countries on operating results and financial position has been disclosed.